In July 2026 an FDA advisory committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon for legal compounding, overruling FDA staff; DSIP was rejected. As of mid-October 2026 none is on the 503A list, so US pharmacies still can't compound them. FDA must accept the advice and write a rule, which has no deadline; a temporary-access policy has been reported but not published.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Can I get BPC-157 or TB-500 from a US compounding pharmacy now?
Not legally yet. As of 9 October 2026 neither is on the 503A bulks list or in FDA's Category 1. The July votes were advisory; FDA must accept them and complete rulemaking first.
What did the committee decide?
It recommended six of seven peptides: BPC-157, KPV and TB-500 (8–6–1), MOTS-c (7–5–2), Semax and Epitalon. It rejected DSIP (6–7–1). FDA staff had recommended against all seven.
Why did FDA staff object?
Mainly quality: the substances are "not well-characterized", injectables carry immunogenicity risk from impurities, and there are almost no human studies by the routes people use. Critics answer that the restrictions pushed users to unregulated vendors instead.1
When could access change?
There is no deadline. Rulemaking has historically taken years; a temporary enforcement-discretion policy was reported by the Washington Post on 7 October 2026 but has not been published.
02What this means for you (as of 15 October 2026)
If you use or want to use BPC-157, TB-500, KPV, MOTS-c, Semax or Epitalon in the US, the July committee vote has not yet changed what a pharmacy can legally make for you. None of the six is on the 503A bulks list (21 CFR 216.23) or in FDA's Category 1, so a 503A compounding pharmacy still has no federal pathway to compound them. The votes were advice; FDA has to accept them and then run notice-and-comment rulemaking (MDside, 9 Oct 2026).
- What did change: in April 2026 FDA took these substances out of Category 2, the "significant safety risk" bucket that had blocked them since 2023. That removed the strongest signal against them, but it is not a listing.
- Timeline: rulemaking has no deadline. FDA proposed five other additions in September 2019, and the list still holds only the six substances from the February 2019 final rule (MDside). Trade analysts expect 8–24 months at minimum once FDA starts.
- A possible shortcut: the Washington Post reported on 7 October 2026 that the administration is drafting a temporary-sale policy for some restricted peptides while rules are written. Nothing has been published. If it comes, it would most likely be enforcement discretion: FDA saying it won't act against pharmacies that meet set conditions, which does not override state pharmacy boards (MDside).
- Even after listing, a compounded peptide is not FDA-approved; the listing rule itself says the data are inadequate to show safety or efficacy of products compounded from listed substances.
03The votes
| Peptide | Use FDA evaluated | Committee vote (yes–no–abstain) | Outcome |
|---|---|---|---|
| BPC-157 | Ulcerative colitis | 8–6–1 | Recommended |
| KPV | Wound healing, inflammatory conditions | 8–6–1 | Recommended |
| TB-500 | Wound healing | 8–6–1 | Recommended |
| MOTS-c | Obesity, osteoporosis | 7–5–2 | Recommended |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | 8–5–1 (reported) | Recommended |
| Epitalon | Insomnia | 7–4–1 or 7–5–1 (reports differ) | Recommended |
| Emideltide (DSIP) | Insomnia, narcolepsy, opioid withdrawal | 6–7–1 | Not recommended |
Swipe table →
FDA staff proposed that all 14 substances (free base and acetate of each) not be listed. Tallies come from trade press and law-firm summaries; FDA had not posted minutes as of 9 October (MDside).
04Criticisms of the restrictions
- They moved people to worse sources. The case made at the meeting and by the compounding industry is that the 2023 Category 2 move did not stop use; it pushed it to "research use only" vendors with no pharmacy oversight. A former Puerto Rico governor told the hearing that "the 2023 restrictions did not raise the standards, they abandoned them." The Alliance for Pharmacy Compounding has asked FDA for interim, patient-specific compounding with cGMP-sourced ingredients and adverse-event reporting.
- Who decides. One yes-voting member said it was "time to put this decision back in the hands of the physician and pharmacist" (RAPS, 23 Jul 2026).
- Narrow review. FDA judged each peptide on one or two indications the nominators proposed, for example BPC-157 only for ulcerative colitis, rather than on how people actually use it. A "no evidence for ulcerative colitis" finding tells you little about tendon or gut-healing use.
- The adverse-event record is thin. The BPC-157 briefing cited three FAERS reports after injection (one injection-site reaction confounded by another compounded peptide, one shortness-of-breath ER visit), and FDA itself called attribution unclear (FDA briefing document).
05Criticisms of the committee vote
- Quality is the real gap. FDA staff found BPC-157 "not well-characterized" for identity and purity, flagged immunogenicity from aggregation and peptide impurities in injectables, and found no human studies by the subcutaneous, oral, nasal or transdermal routes people use (FDA briefing document). Without a USP monograph, all of that testing falls on the individual compounder (Willis & Vu 2026, PMID 42752426).
- Thin efficacy data. No-voters cited the "lack of efficacy data and randomized controlled trials"; for Epitalon one member also raised a possible carcinogenicity signal.
- Panel make-up. FDA added eight new committee members in June 2026, several reported to have ties to peptide prescribing (STAT, 29 Jun 2026), then added temporary voting members with academic backgrounds before the meeting (Bloomberg Law). HHS Secretary Robert F. Kennedy Jr. had publicly backed wider access.
06What to watch
- A Federal Register notice (proposed rule) or a new FDA guidance on interim compounding. Docket FDA-2025-N-6895; the 503A bulks list page is where a listing would appear.
- The next committee round, planned before the end of February 2027, for GHK-Cu, Melanotan II, LL-37, Dihexa and PEG-MGF.
- Your state board of pharmacy: it applies its own rules regardless of what FDA does.
07Connections
08Sources
- Willis J, Vu N. Synthetic peptides in pharmacy compounding: analysis of PCAC recommendations and industry safety standards. Int J Pharm Compd 2026. PMID 42752426PubMed 42752426
09Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.